Navigation Links
Cytopia Commences Phase II Cancer Drug Study
Date:12/17/2007

Cytopia's first Phase II clinical trial

MELBOURNE, Australia, Dec. 18 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has obtained regulatory approval to proceed with a Phase II clinical study assessing its lead anti-cancer drug in up to 24 multiple myeloma patients. Patient enrolment will soon commence.

This Phase II study is the first in a number of further clinical studies planned for the anti-cancer vascular-disrupting agent CYT997 and will be conducted at the Alfred Hospital in Melbourne, Australia. It will investigate the activity of CYT997 in patients with relapsed or refractory multiple myeloma.

Multiple myeloma is an incurable cancer of plasma cells of the bone marrow, where the cells divide in an uncontrolled manner invading not only the marrow but the solid bone tissue. The human clinical trial follows promising laboratory studies which indicate that CYT997 potently disrupts myeloma cells, including those collected from patients with the disease.

While some significant advances in myeloma therapy have occurred in recent years, disease recurrence almost always occurs with increasing drug resistance leading to uncontrollable and fatal disease.

To be eligible for the study, patients must have failed at least one previous line of approved therapy. The trial is a single-arm, two-stage design with an interim analysis after 14 patients and maximum enrolment of 24 subjects. The company anticipates releasing interim data for this study in the third quarter of 2008.

"We are keen to unlock the potential of CYT997 as a next-generation cancer drug, particularly in indications with unmet medical need," said Mr Andrew Macdonald, CEO of Cytopia. "This study is the first of Cytopia's planned suite of Phase II studies for CYT997 and is a substantial value-adding milestone for the company."

The market for multiple myeloma drugs was estimated at US$930 million in 2006 and is expected to grow to approximately US$3 billion by 2013.

Cytopia is also currently conducting a Phase I study investigating the safety and tolerability of CYT997 following oral administration. The company also intends to file regulatory applications in support of other Phase II studies over the coming months.

The following table provides a summary of the key aspects of the Phase II multiple myeloma trial.

Name of trial A prospective, single-arm, two-stage, open-label

Phase II trial of CYT997 in relapsed and

refractory multiple myeloma (CCL07001)

Primary endpoints Determination of the overall response rate to CYT997

Secondary endpoints Time to progression; number of cycles of CYT997 to

achieve maximum response; overall survival and

safety and tolerability

Blinding status Not blinded

Product development Drug substance and drug product are manufactured to

status GMP standards

Treatment method

Route 24 hour intravenous infusion dose

Frequency Days 1 and 8 of a 21 day cycle

Dose-levels 202 mg/m2 CYT997 dihydrochloride

Number of trial 24 patients maximum

subjects

Subject selection Eligible patients must have a diagnosis of

criteria multiple myeloma (per World Health Organisation

criteria) and have received at least one but no

more than three previous lines of therapy

Trial location Melbourne, Australia

Expected completion Interim analysis (14 patients) Q3, 2008

Trial standard ICH-GCP

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Exelixis Commences Public Offering of Common Stock
3. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
4. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
5. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
6. Ovation further advances development pipeline with new phase III epilepsy study
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Manic phase of bipolar disorder benefits from breast cancer medication
11. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official ... NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in ... from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been updated by ... design and the developer has fixed known bugs within the app. Calls Blacklist allows ... phone while not consuming any of their device’s battery power or memory. It provides ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... In response to the opioid abuse epidemic, today ... Medical Products and Tobacco, along with other FDA leaders, called ... to opioid medications. The plan will focus on policies aimed ... access to effective relief. --> ... the risk-benefit paradigm for opioids and ensure that the agency ...
Breaking Medicine Technology: